Hourly refreshMon, Oct 26, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Biotech & pharma

2,126 press releases in English indexed under biotech & pharma.

Clear all filters
Keywords, dates and language
Sources
up to 10
Newswires (50)
Company newsrooms (91)
Companies
Releases linked to any of up to 10 companies
AllFinanceCryptoAISaaSHealthcareReal estateEnergyRetailAutomotiveGamingMediaEducation
+ 33 more topics
TelecomTravelFood & drinkFashion & luxurySportsIndustrialAerospace & defenseLogisticsBiotech & pharmaCybersecuritySemiconductorsSustainabilityBankingInsuranceInvesting & marketsPayments & fintechLegalGovernment & policyNonprofitsJobs & workplaceMarketing & advertisingSoftware & ITCloud & data centersInternet & appsConsumer electronicsConsumer goodsEntertainmentMedical devicesConstruction & engineeringChemicals & materialsMining & metalsOil & gasAgriculture
DownloadExcelTXT
Healthcare · Biotech & pharma

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

- ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets - TOKYO, Aug. 24, 2026 -- Astellas Pharma Inc. (TSE: 4503,...

Aug 24 · 23:30PR Newswire
Healthcare · Biotech & pharma

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood...

Aug 24 · 23:12PR Newswire
Biotech & pharma

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy CAPR securities between December 17, 2025 and July 26, 2026?

Aug 24 · 23:10GlobeNewswire
Finance · Biotech & pharma

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 24, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff...

Aug 24 · 23:06PR Newswire
Finance · Biotech & pharma

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 24, 2026 -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus...

Aug 24 · 23:01PR Newswire
Finance · Biotech & pharma

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

GERMANTOWN, Md., Aug. 24, 2026 -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. (“Clywedog”) in an all-stock transaction.

Aug 24 · 22:57GlobeNewswire
Healthcare · Biotech & pharma

BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICESVancouver, British Columbia--(August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta...

Aug 24 · 22:42Newsfile
Finance · Biotech & pharma

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

DUBLIN, August 24, 2026--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,

Aug 24 · 22:30Business Wire
Finance · Biotech & pharma

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

NEW YORK, Aug. 24, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026.

Aug 24 · 22:06GlobeNewswire
Healthcare · Energy

Theralase(R) Closes C$3.6 Million Brokered Financing

Toronto, Ontario--(August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500...

Aug 24 · 21:01Newsfile
Finance · Biotech & pharma

Capricor Therapeutics, Inc. Investor Alert - Robbins LLP Reminds CAPR Investors with Significant Losses of the Opportunity to Lead the Class Action Lawsuit Against the Company

SAN DIEGO, Aug. 24, 2026 -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026...

Aug 24 · 20:32PR Newswire
Finance · Healthcare

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

VAUGHAN, Ontario, August 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.

Aug 24 · 20:30Business Wire